Author: Zeena Haress 

Higher Power or Smarter Choice

At first glance, larger photobiomodulation (PBM) panels or higher light output
can seem more impressive. In many wellness contexts, “more” is often marketed
as “better.” But the brain is not a muscle or skin surface̶it is a highly sensitive,
electrically active organ with tight metabolic and redox regulation. Here, the goal
is not maximum light delivery, but optimal light delivery: the right dose, in the
right place, consistently.

CeraThrive exemplifies this philosophy. Rather than flooding the brain with high
irradiance, it delivers targeted neuromodulation, designed around biological
sensitivity, controlled dosing, and reproducibility.

Biological Signalling, Not Brute Force

Photobiomodulation (often shortened to PBM), uses red and near-infrared light
to influence cellular processes, particularly mitochondrial activity via cytochrome
c oxidase. Light absorption triggers ATP production, nitric oxide release, oxygen
metabolism, blood flow changes, and low-level reactive oxygen species (ROS)
signalling.

These are not simple energy inputs; they are biological signals that regulate inflammation, metabolism, and repair. Critically, these responses are dose-
sensitive: a small, well-calibrated stimulus can support optimal signalling, whereas uncontrolled high-intensity light may disrupt these processes.

The Biphasic Dose Response: Finding The Brainʼs Optimal Light Window
One of the most important principles in PBM is the biphasic dose response. This
means that light can produce beneficial effects within an optimal dose window,
but weaker effects, no effects, or inhibitory effects outside that window.
In simpler terms:

This inverted-U response emphasizes that precision is more important than raw
power, particularly in the brain.

The Brainʼs Sensitivity

The brain is one of the most metabolically active organs in the body. Despite its
small mass, the brain consumes a disproportionate amount of energy to
maintain synaptic activity, ion gradients, and network function. Neurons are
highly sensitive to mitochondrial changes, ROS, calcium, and excitability. PBM
can support these processes, but only within controlled dose ranges. 

From Concept to Reality

While conceptual arguments about precision are important, they must be
quantitatively grounded. Published neurological tPBM studies show that effective
irradiance ranges are modest, often in the 10‒50 mW/cm2 range, with fluences
between 3‒60 J/cm2 depending on session duration, wavelength, and anatomical
target. These ranges are lower than those commonly used in large-body
wellness panels, reinforcing the need for targeted dosing.

So, while a large panel may be appropriate for general wellness, muscle
recovery, or skin exposure, it is not automatically the ideal tool for brain-focused
PBM: The comparison is not equal because the biological target is not the same.

Positioning CeraThrive

CeraThriveʼs headband delivers 20‒30 mW/cm2 across multiple wavelengths
(630, 850, 940, 1070 nm), squarely within the therapeutic range identified in the
literature. The abdominal pad contributes ~26 mW/cm2 at 630 and 850 nm,
producing a combined surface irradiance of ~52 mW/cm2 across a larger area.
The dual approach allows precise cortical neuromodulation via the headband
while enhancing systemic mitochondrial signalling through the body pad.
Importantly, both stay within safe and effective parameters, respecting PBMʼs
biphasic response and avoiding overstimulation,

Neurological tPBM Parameters vs. CeraThrive

This table synthesizes published ranges from Hamblin (2017), Naeser et al. (2016), and Salehpour et al. (2018) and overlays CeraThrive device metrics for comparison

Precision > Power

For brain applications, a lower-powered PBM device is not necessarily
“underpowered.” Such a device may be designed around a different therapeutic
logic, delivering a controlled, biologically appropriate dose rather than maximal
irradiance. In the brain, the goal is not to heat tissue or force stimulation, but to
support subtle cellular and network-level regulation. Thus, the correct
benchmark is optimal dose within the therapeutic window, not raw power.
Precision ensures consistent cortical targeting, effective mitochondrial
modulation, and reproducible neuromodulatory outcomes, making carefully
controlled dosing more important than sheer output.

CeraThrive exemplifies a brain-focused PBM approach built around targeted
delivery and controlled dosing, rather than raw power. Unlike broad high-output
panels, which may be appropriate for skin or muscle, brain photobiomodulation
requires precision: respecting tissue sensitivity, operating within the biphasic
dose-response window, and supporting subtle cellular and network-level
regulation. Lower irradiance is not a limitation. It is intentional, reflecting
therapeutic logic that prioritizes optimal dose over intensity.
The future of brain PBM lies in precision-guided, evidence-based
neuromodulation, where modest, carefully applied light achieves more than
brute-force output ever could.

References

1. de Freitas, L. F., & Hamblin, M. R. (2016). Proposed mechanisms of
   photobiomodulation or low-level light therapy. IEEE Journal of Selected
   Topics in Quantum Electronics, 22(3), 7000417. Available via PubMed
   Central.
2. Hamblin, M. R. (2017). Photobiomodulation for traumatic brain injury and
   stroke. Journal of Neuroscience Research, 96(4), 731‒743. Available via
   PubMed Central.
3. Huang, Y. Y., Chen, A. C. H., Carroll, J. D., & Hamblin, M. R. (2009). Biphasic
   dose response in low level light therapy. Dose-Response, 7(4), 358‒383.
   Available via PubMed Central.
4. Huang, Y. Y., Sharma, S. K., Carroll, J., & Hamblin, M. R. (2011). Biphasic dose
   response in low level light therapy: An update. Dose-Response, 9(4), 602‒
   618. Available via PubMed Central.
5. Lin, H., et al. (2024). Transcranial photobiomodulation for brain diseases.
   Neural Regeneration Research. Available via PubMed Central.
6. Naeser, M. A., et al. (2016). Transcranial, red/near-infrared light-emitting
   diode therapy to improve cognition in chronic traumatic brain injury.
   Photomedicine and Laser Surgery, 34(12), 610‒626. Available via PubMed.
7. Salehpour, F., Mahmoudi, J., Kamari, F., Sadigh-Eteghad, S., Rasta, S. H., &
   Hamblin, M. R. (2018). Brain photobiomodulation therapy: A narrative review.
   Molecular Neurobiology, 55, 6601‒6636. Available via PubMed Central.
8. Yan, B., et al. (2025). Unlocking the potential of photobiomodulation therapy
   for neurological disorders. Frontiers in Neuroscience. Available via PubMed
   Central.
9. De Ridder, D., Hamblin, M. R., & Vanneste, S. (2026). Transcranial
   photobiomodulation for neuromodulation of brain disorders: A perspective.
   Neuromodulation. Advance online publication. https://doi.org/10.1016/
   j.neurom.2025.12.006
10. Basha, S., Shivappa, P., Biswas, S., Prabhu, V., Prabhu, S. S., Pai, A. R., &
    Mahato, K. K. (2025). From light to healing: Photobiomodulation therapy in
    medical disciplines. Journal of Translational Medicine, 23(1), Article 1430.
    https://doi.org/10.1186/s12967-025-07466-3
11. Naeser, M. A., Zafonte, R., Krengel, M. H., Martin, P. I., Frazier, J., Hamblin, M.
    R., & Knight, J. A. (2016). Transcranial, red/near-infrared light-emitting diode
    therapy to improve cognition in chronic traumatic brain injury. Photomedicine
    and Laser Surgery, 34(12), 610‒626. https://doi.org/10.1089/
    pho.2016.4171Salehpour, F., Mahmoudi, J., Kamari, F., Sadigh-Eteghad, S., Rasta, S. H.
12. Hamblin, M. R. (2018). Brain photobiomodulation therapy: A narrative review.
    Molecular Neurobiology, 55(8), 6601‒6636. https://doi.org/10.1007/
    s12035-017-0852-4